Drug intelligence / Profile preview

EDIT-201

Development stage: Discontinued
Lead developer: Editas Medicine
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

EDIT-201 is an experimental, allogeneic, CRISPR-edited natural killer (NK) cell therapy developed by Editas Medicine for the treatment of solid tumors. The therapy utilizes the company's proprietary SLEEK (Selection by Licensed Effector Cell Knock-out) gene-editing technology and the AsCas12a (Cpf1) nuclease to perform high-efficiency multi-gene editing. Specifically, EDIT-201 is designed to enhance the effector function, persistence, and metabolic fitness of NK cells within the immunosuppressive tumor microenvironment by knocking out specific inhibitory genes. In January 2023, Editas Medicine announced a strategic reprioritization to focus on its lead clinical program (EDIT-301) and in vivo CRISPR medicines, leading to the discontinuation of internal development for its NK cell programs, including EDIT-201.

Other names: CRISPR-edited NK cellsSLEEK-NK cells

Targets

CISH (Cytokine-inducible SH2-containing protein)TGFBR2 (TGF-β receptor type 2)

Beyond the preview

Go deeper on EDIT-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EDIT-201.

Explore the full profile